Here are the DEF 14A proxy statements from enGene Therapeutics Inc. Warrants (ENGNW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ENGNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENGNW filings page.
enGene Therapeutics Inc. is asking shareholders to vote at a virtual-only annual general meeting on June 9, 2026. Holders of common shares at the April 28, 2026 record date can participate online, vote, and submit questions via live audio webcast.
Shareholders will vote on electing four directors to three-year terms and on appointing KPMG as auditors, with the board recommending “FOR” on both items. Quorum requires at least two persons representing at least 33⅓% of shares entitled to vote.